Close
Novotech
Jabsco PureFlo 21 Single Use

Aptar Pharma names Jean-Marc Pardonge as prescription division new president

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.
- Advertisement -

Aptar Pharma, a subsidiary of Aptargroup, has named Jean-Marc Pardonge as the new president for the company’s prescription division.

The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices.

In 2000 Pardonge served as R&D manager for Aptar Pharma’s prescription division and promoted to R&D vice president in 2003.

In January 2010, Pardonge served as global market development president for Aptar Pharma’s prescription division, where he managed and coordinated worldwide activities which included scientific and regulatory affairs, business development, communication, engineering, innovation, marketing, projects and R&D.

The market for prescription division will be leveraged with Pardonge’s knowledge in both the pharmaceutical market and the division’s customers, claims the company.

 

Latest stories

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.

Early Insights Reduce Risk in Drug Development Programs

Leveraging early-stage data and translational research allows pharmaceutical companies to mitigate drug development risk and implement adaptive strategies for higher success.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »